Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma

In this paper, Dr. Gael Roué and his colleagues at the IDIBAPS in Barcelona and scientists from Constellation Pharmaceuticals presented evidence of a synergistic anti-tumor activity of lenalidomide in combination with a BET inhibitor in bortezomib-resistant mantle cell lymphoma cell lines. They show that exacerbated IRF4/MYC signaling is associated to bortezomib resistance in MCL in vivo and warrant clinical evaluation of lenalidomide plus BET inhibitor combination in MCL cases refractory to proteasome inhibition.

View full paper here